Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Merck & Co (NY: MRK ) 101.64 -0.24 (-0.24%) Streaming Delayed Price Updated: 2:45 PM EST, Nov 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Merck & Co < Previous 1 2 3 4 5 6 7 8 9 ... 94 95 Next > Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More October 03, 2024 EQNX::TICKER_START (NYSE:ANVS),(NYSE:JNJ),(NYSE:NVS),(NYSE:MRK),(NYSE:GSK) EQNX::TICKER_END Via FinancialNewsMedia Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers. October 03, 2024 Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain. Via Investor's Business Daily Topics Stocks Exposures US Equities The Covid Era Tech Promises To Reinvent Cancer Treatment October 01, 2024 Pfizer Inc (NYSE: PFE) made a promise to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: MRNA) in turning to oncology for its next growth story. Via Benzinga Exposures COVID-19 Is Merck Stock a Buy? September 29, 2024 There is mounting pressure on the company's most prized franchise. Via The Motley Fool This Is What Whales Are Betting On Merck & Co September 25, 2024 Via Benzinga Merck & Co Unusual Options Activity For September 23 September 23, 2024 Via Benzinga Exploring NYSE:MRK's dividend characteristics. September 20, 2024 Why the dividend investor may take a look at MERCK & CO. INC. (NYSE:MRK). Via Chartmill How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit October 01, 2024 How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit Via News Direct Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical October 01, 2024 From Merck & Co., Inc. Via Business Wire Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31 October 01, 2024 From Merck & Co., Inc. Via Business Wire 2 High-Potential Growth Stocks You Shouldn't Overlook September 29, 2024 These two growth stocks have plenty of room to run. Via The Motley Fool Behind the Scenes of Merck & Co's Latest Options Trends September 18, 2024 Via Benzinga NYSE:MRK: good value for what you're paying. September 18, 2024 MERCK & CO. INC. (NYSE:MRK) appears to be flying under the radar despite its strong fundamentals. Via Chartmill Evaxion Biotech Partners With Merck To Expand Vaccine Development September 26, 2024 Evaxion Biotech enters an expanded collaboration with Merck, granting an option to license preclinical vaccine candidates. The deal includes $3.2 million upfront and potential earnings up to $592... Via Benzinga Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024 September 26, 2024 From Merck & Co., Inc. Via Business Wire FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients September 25, 2024 The FDA's advisory committee is set to evaluate the use of PD-1 inhibitors in gastric cancer patients, focusing on the risks and benefits for those with varying PD-L1 levels, including low expressers. Via Benzinga Exposures Product Safety Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years September 25, 2024 Eli Lilly presents promising long-term data showing Ebglyss' efficacy in treating moderate-to-severe atopic dermatitis, with over 80% of patients maintaining clear skin for up to three years. FDA and... Via Benzinga Exposures Product Safety Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study September 25, 2024 Merck's Phase 3 KEYFORM-007 study on the combination of favezelimab and pembrolizumab in MSS mCRC patients did not improve overall survival compared to standard treatments, though safety remained... Via Benzinga Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer September 25, 2024 From Merck & Co., Inc. Via Business Wire Merck’s KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma September 25, 2024 From Merck & Co., Inc. Via Business Wire Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus September 24, 2024 From Merck & Co., Inc. Via Business Wire Pfizer Advances On Its Cancer Journey September 20, 2024 On Saturday, Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer cachexia during the European Society for Medical Oncology 2024... Via Benzinga Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers September 20, 2024 From Merck & Co., Inc. Via Business Wire How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs September 20, 2024 EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:MRK),(NYSE:PFE),(NASDAQ:GLMD) EQNX::TICKER_END Via FinancialNewsMedia Is It Too Late to Buy ServiceNow Stock? September 20, 2024 The stock is up nearly 60% since the beginning of the year. Via The Motley Fool How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs September 20, 2024 From FN Media Group LLC Via GlobeNewswire 2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? September 19, 2024 Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares. Via Investor's Business Daily Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer September 18, 2024 The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line treatment of advanced or metastatic malignant pleural mesothelioma. Via Benzinga Exposures Product Safety This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous. September 18, 2024 There's a lot of hope for ivonescimab, but are investors being a bit too bullish? Via The Motley Fool FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM) September 18, 2024 From Merck & Co., Inc. Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 ... 94 95 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
